Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 21, 2026Annals of HematologyOpen Access

Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

LNL I Choo NgSingHealthJTJ S TanNational University of SingaporeSOShin Yeu OngSingapore General Hospital

Discussion

Loading...

Member takes

Implication

Randomized trial shows improved responses with brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma, suggesting a shift in treatment approaches.

Key Points

  • Evaluate the efficacy and safety of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma, especially in Asian populations.
  • Five patients with relapsed/refractory mantle cell lymphoma received brexucabtagene autoleucel at Singapore General Hospital between April and December 2025.
  • Historical cohort of patients who underwent allogeneic haematopoietic stem cell transplantation was compared for outcomes.
  • Overall response rate (ORR) for brexu-cel cohort was 100%, with complete response rate (CRR) of 80%.
  • Cytokine release syndrome occurred in 80% of patients, while only one patient developed grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS).
  • Efficacy and safety outcomes for brexu-cel were favorable when compared to historical cohorts undergoing allo-HSCT.

Cite This Study

Ng et al. (2026) studied this question.

synapsesocial.com/papers/6a37815a24f042ddf4c5b360https://doi.org/10.1007/s00277-026-07126-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT2026 · 1 citations
  2. 2Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study2025 · 1 citations
  3. 3Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,746 citations
  4. 4Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults2025 · 6 citations
  5. 5Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries2026 · 15 citations